1. A Comparison of Fluoxetine Imipramine and Placebo in Patients with Bipolar Depressive Disorder
- Author
-
Gloria Collins, Earleen Ashbrook, J. F. Wernicke, and Jay B. Cohn
- Subjects
Adult ,Male ,Imipramine ,medicine.medical_specialty ,Bipolar Disorder ,Adolescent ,Lithium ,Placebo ,Placebos ,Random Allocation ,Pharmacotherapy ,Double-Blind Method ,Fluoxetine ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,In patient ,Bipolar disorder ,Depression (differential diagnoses) ,Aged ,Psychiatric Status Rating Scales ,Study drug ,business.industry ,Middle Aged ,medicine.disease ,Psychiatry and Mental health ,Female ,business ,medicine.drug - Abstract
This was a 6-week, double-blind comparison of fluoxetine, imipramine, and placebo in 89 patients with bipolar depression. Using the criteria of greater than or equal to 50% improvement in the HAMD-total score after at least 3 weeks on study drug, endpoint analysis showed 86% of the fluoxetine-treated patients improved compared with 57% of the imipramine-treated and 38% of the placebo-treated patients. Significantly fewer fluoxetine-treated patients discontinued due to adverse events than did imipramine-treated patients (7% vs. 30%, respectively).
- Published
- 1989
- Full Text
- View/download PDF